Search research articles
Contact Us
Filters
Showing results (41-50 of 85) with videos related to
Page
of 9
Sort By:
ACS Chemical Biology
|
January 11, 2023
Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target
Yi Liao, Sean Chin Chan, Eric A Welsh, et al.
The Journal of Biological Chemistry
|
October 2, 2022
Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer
Ou Deng, Sweta Dash, Thales C Nepomuceno, et al.
Molecular Pharmacology
|
April 2, 2021
Novel Human-Derived <i>RET</i> Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling
Laura Schubert, Anh T Le, Adriana Estrada-Bernal, et al.
Proteomics
|
May 11, 2010
MASPECTRAS 2: An integration and analysis platform for proteomic data
Ceereena Ubaida Mohien, Jürgen Hartler, Florian Breitwieser, et al.
Cell Chemical Biology
|
October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2
Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Molecular Cancer Therapeutics
|
September 6, 2014
Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics
Manuela Gridling, Scott B Ficarro, Florian P Breitwieser, et al.
Nature Chemical Biology
|
October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomics
Brent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Molecular Oncology
|
November 8, 2017
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition
Manali Phadke, Lily L Remsing Rix, Inna Smalley, et al.
Nature Chemical Biology
|
March 2, 2010
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Jiannong Li, Uwe Rix, Bin Fang, et al.
Blood
|
August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
Uwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 85) with videos related to
Sort By:
Page
of 9
ACS Chemical Biology
|
January 11, 2023
Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target
Yi Liao, Sean Chin Chan, Eric A Welsh, et al.
The Journal of Biological Chemistry
|
October 2, 2022
Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer
Ou Deng, Sweta Dash, Thales C Nepomuceno, et al.
Molecular Pharmacology
|
April 2, 2021
Novel Human-Derived <i>RET</i> Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling
Laura Schubert, Anh T Le, Adriana Estrada-Bernal, et al.
Proteomics
|
May 11, 2010
MASPECTRAS 2: An integration and analysis platform for proteomic data
Ceereena Ubaida Mohien, Jürgen Hartler, Florian Breitwieser, et al.
Cell Chemical Biology
|
October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2
Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Molecular Cancer Therapeutics
|
September 6, 2014
Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics
Manuela Gridling, Scott B Ficarro, Florian P Breitwieser, et al.
Nature Chemical Biology
|
October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomics
Brent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Molecular Oncology
|
November 8, 2017
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition
Manali Phadke, Lily L Remsing Rix, Inna Smalley, et al.
Nature Chemical Biology
|
March 2, 2010
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Jiannong Li, Uwe Rix, Bin Fang, et al.
Blood
|
August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
Uwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
Page
of 9